Immunogenicity and safety of co-administration of adjuvanted respiratory syncytial virus prefusion F protein vaccine with 20-valent pneumococcal conjugate vaccine in adults aged ≥60 years: a randomized, non-inferiority trial

Isabel Leroux‐Roels; Muriel Lins; Ronald Surowitz; Antoinette Pragalos; Paulia Kwo Ton Ge Jua; Dominique Wauters; Amulya Jayadev; Jacqueline Elaine Akite; Archana Jastorff; Vicky Cárdenas; Marie Van der Wielen; the RSV-019 study group; Abram Burgher; Adeyemi Gbohunmi; Agnieszka Jurek-Urbanowska; Bruce Rankin; Carlos Brotons Cuixart; Ewa Krecipro Nizinska; Fernando Cereto Castro; Jay Sandberg; Jean Benoit Martinot; Joseph Soufer; Katarzyna Wawrzyniec-Lis; Kathleen Jones; Klaas Vercruysse; Lina Perez Breva; Luc Capiau; Magda Dabrowska; Manuchehr Darani; Miguel Trevino; Patrick Dennis; Patrick Soentjens; Przemysław Borowy; Rachel Presti; Rica Santiago; Salma Saiger; Sander Gothard; Shital Upadhyay; Tatyana Miroshnikova; William Nixon; Madhavi Ampajwala

doi:10.1093/cid/ciag250

April 10, 2026Clinical Infectious DiseasesOpen Access

Immunogenicity and safety of co-administration of adjuvanted respiratory syncytial virus prefusion F protein vaccine with 20-valent pneumococcal conjugate vaccine in adults aged ≥60 years: a randomized, non-inferiority trial

View Full Paper

Ask AI

Bookmark

Share

Key Points

To determine the immunogenicity and safety of co-administering RSVPreF3 and PCV20 vaccines in adults aged 60 and older.
Participants received either the co-administered vaccines or the vaccines sequentially
Assessed immunogenicity and safety outcomes
Co-administration exhibited non-inferior immunogenicity compared to sequential administration
Both vaccines had an acceptable safety profile
Support for co-administration enhances vaccine uptake

Implication

Shows co-administering RSV and pneumococcal vaccines is safe and effective in older adults, suggesting improved vaccine uptake.

Abstract

Co-administration of adjuvanted RSVPreF3 vaccine and PCV20 vaccine in older adults is immunologically non-inferior to their sequential administration, with an acceptable safety profile. These findings support co-administration as a strategy to enhance vaccine uptake.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Leroux‐Roels et al. (2026) studied this question.

synapsesocial.com/papers/69e471c5010ef96374d8dfcb https://doi.org/10.1093/cid/ciag250

View Full Paper

Ask AI

Bookmark

Share

Immunogenicity and safety of co-administration of adjuvanted respiratory syncytial virus prefusion F protein vaccine with 20-valent pneumococcal conjugate vaccine in adults aged ≥60 years: a randomized, non-inferiority trial

Key Points

Implication

Abstract

Discussion

Cite This Study

Immunogenicity and safety of co-administration of adjuvanted respiratory syncytial virus prefusion F protein vaccine with 20-valent pneumococcal conjugate vaccine in adults aged ≥60 years: a randomized, non-inferiority trial

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Clinical Infectious Diseases

Keep reading

More related papers

More from Clinical Infectious Diseases